In‐transit cutaneous squamous cell carcinoma

Luke S McLean and Danny Rischin
Med J Aust 2022; 216 (8): . || doi: 10.5694/mja2.51486
Published online: 2 May 2022

  • Luke S McLean
  • Danny Rischin

  • Peter MacCallum Cancer Centre, Melbourne, VIC


Competing interests:

Danny Rischin receives institutional research funding from MSD, Bristol–Myers Squibb, GSK and Roche. He participates in trial steering committees and/or advisory boards (all uncompensated) for MSD, GSK, Regeneron and Sanofi.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.